Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › EMCURE

EMCURE

Emcure Pharmaceuticals Limited
Small-capPharma ↗

What the six lenses say about EMCURE — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1809.5
2026-07-10
VWAP · 1Y anchor
₹1498
+20.8% from VWAP
P/E · TTM
37.1×
TTM EPS ₹48.8
52-week range
89%
position low→high
RSI(14)
54
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How EMCURE’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.5
avg conviction decile
Leadership
0/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD888›

The actual numbers

Price vs VWAP (1y)+20.8%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+15.4%
Price vs 50-EMA+3.7%
RSI(14)54
RS vs Nifty 500 · 3M+9.8%
RS vs sector · 3M-2.7%
52-week range89%
Volume vs 30d avg0.35×
Volume vs 60d avg0.30×
ATR(14) · volatility55.6
Bollinger width · vol contraction0.108
FundamentalD1079›

The actual numbers

Return on equity (ROE)20.1%
Return on capital (ROCE)24.0%
Operating margin15.5%
Net margin10.2%
Revenue growth · YoY+16.6%
EPS growth · YoY+34.1%
Debt / equity0.31×

Full 8-quarter history in the financials table below.

ValuationD315›

The actual numbers

P/E (TTM)37.1×
TTM EPS₹48.8
52-week range89%
CatalystD537›

The actual numbers

Earnings & momentum35
Capital actions10
Governance101

Every filing in the corporate-announcements panel below.

FlowD550›

The actual numbers

Promoter holding77.9%
Delivery · 30d avg47.6%
Up/down-day asymmetry0.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D8 + D5 ) ÷ 2 = 6.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
84
Conviction score 84/100 · avg-decile strength 6.5/10
Conviction score84/100›
TechnicalD8›
FundamentalD10›
ValuationD3›
CatalystD5›
FlowD5›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-0.3pp
-1.7pp
+1.3pp
+13.4pp
+24.2pp
+46.5pp
Nifty 500
Broad-market baseline
-0.7pp
-1.7pp
+0.7pp
+9.8pp
+19.1pp
+42.7pp
Sector
Own-sector index
—
—
-1.7pp
-2.7pp
+4.7pp
+24.8pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

EMCURE daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1809.50+0.20

Relative strength

RS vs baseline · rebased to 100

EMCURE ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
132.54-0.99

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,8152,0021,9632,1162,1012,2702,3632,470
↳ change QoQ—+10.3%-2.0%+7.8%-0.7%+8.0%+4.1%+4.5%
EBITDA (₹cr)360417359402417475493480
EBITDA margin19.8%20.8%18.3%19.0%19.9%20.9%20.9%19.4%
PAT (₹cr)153202156197215251231244
↳ change QoQ—+32.1%-22.6%+26.2%+9.1%+16.7%-8.0%+5.6%
Net margin8.4%10.1%8.0%9.3%10.2%11.1%9.8%9.9%
EPS (₹)7.9510.338.129.9710.9212.8412.1612.84
D/E————————
YoY growth · Mar '26Revenue +16.7% YoYPAT +23.9% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 19 Jun '26
    LOWgovernance
    ESOP/ESOS/ESPS
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Jun '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 27 May '26
    LOWgovernance
    Allotment of Securities
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 16 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 May '26
    LOWgovernance
    Change in Management
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 May '26
    LOWgovernance
    Change in Management
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 May '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 5 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds EMCURE

Mutual funds holding EMCURE (10)

FundWeightAUM ₹crGrade
Kotak Midcap Reg Gr0.98%67,611
Nippon India Multi Cap Dir Bns0.58%54,585
Nippon India Multi Cap Gr0.58%54,585
Nippon India Multi Cap Bns0.58%54,585
SBI Flexicap Reg Gr0.91%22,685
HSBC Small Cap Fund Reg Gr0.75%16,877
Aditya BSL ELSS Tax Saver Gr1.61%14,249
Aditya BSL ELSS Tax Saver Gr LSP1.61%14,249
Nippon India Pharma Gr1.52%9,044
Nippon India Pharma Bns1.52%9,044

ETFs holding EMCURE (0)

No tracked ETF holds EMCURE ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma